Drug Trial Radar · NCT07431827
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Mar 18, 2026
Primary completion
Oct 26, 2039
Study completion Oct 26, 2039
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Feb 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3, randomized, double-blind study of adjuvant calderasib plus subcutaneous pembrolizumab and berahyaluronidase alfa (MK-3475A) versus adjuvant placebo plus MK-3475a in participants with completely resected stage IIA-IIIB (N2), KRAS G12C-mutant non-small cell lung cancer following receipt of either neoadjuvant pembrolizumab plus chemotherapy or adjuvant chemotherapy. The primary goal of the study is to compare adjuvant calderasib plus MK-3475A to adjuvant placebo plus MK-3475A with respect to disease-free survival (DFS) as assessed by the investigator.
Conditions
- Non-small Cell Lung Cancer
Interventions
CalderasibDrug
MK-1084 oral tablet
MK-3475ABiological
Fixed dose coformulated product of hyaluronidase/pembrolizumab administered via SC injection.
PlaceboDrug
Placebo oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-free Survival (DFS)Time frame: Up to ~11 years
Locations
125 sites in 19 countries. Site status is shown where the registry gives one.
Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0306)
CABA, Argentina · Recruiting
Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC) ( Site 0309)
CABA, Argentina · Recruiting
Instituto Alexander Fleming ( Site 0310)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Sanatorio Parque ( Site 0311)
Rosario, Santa Fe Province, Argentina · Recruiting
Northern Beaches Hospital ( Site 3009)
Frenchs Forest, New South Wales, Australia · Recruiting
Princess Alexandra Hospital ( Site 3012)
Woolloongabba, Queensland, Australia · Recruiting
Peninsula University Hospital ( Site 3011)
Frankston, Victoria, Australia · Recruiting
Hospital Alemao Oswaldo Cruz ( Site 0416)
São Paulo, Brazil · Recruiting
PRONUTRIR ( Site 0425)
Fortaleza, Ceará, Brazil · Recruiting
AFECC ASSOCIACAO FEMININA EDUCACAO COMBATE CANCER ( Site 0414)
Vitória, Espírito Santo, Brazil · Recruiting
Hospital Madre Teresa ( Site 0420)
Belo Horizonte, Minas Gerais, Brazil · Recruiting
Real Hospital Portugues ( Site 0418)
Recife, Pernambuco, Brazil · Recruiting
Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0402)
Porto Alegree, Rio Grande do Sul, Brazil · Recruiting
Faculdade de Medicina do ABC ( Site 0415)
Santo André, São Paulo, Brazil · Recruiting
Instituto do Câncer Brasil - Unidade Taubaté ( Site 0424)
Taubaté, São Paulo, Brazil · Recruiting
Moncton Hospital ( Site 0200)
Moncton, New Brunswick, Canada · Recruiting
CIUSSS- saguenay-Lac-Saint-Jean ( Site 0216)
Chicoutimi, Quebec, Canada · Recruiting
Centre Hospitalier de l'Université de Montréal ( Site 0219)
Montreal, Quebec, Canada · Recruiting
Clínica MEDS La Dehesa ( Site 0509)
Lo Barnechea, Region M. de Santiago, Chile · Recruiting
Fundación Arturo López Pérez ( Site 0501)
Santiago, Region M. de Santiago, Chile · Recruiting
Centro de Oncología de Precisión ( Site 0503)
Santiago, Region M. de Santiago, Chile · Recruiting
Bradford Hill ( Site 0508)
Santiago, Region M. de Santiago, Chile · Recruiting
Peking University People's Hospital ( Site 2100)
Beijing, Beijing Municipality, China · Recruiting
Beijing Cancer hospital ( Site 2106)
Beijing, Beijing Municipality, China · Recruiting
Peking Union Medical College Hospital ( Site 2105)
Beijing, Beijing Municipality, China · Recruiting
Chongqing University Three Gorges Hospital ( Site 2138)
Chongqing, Chongqing Municipality, China · Recruiting
The First Affiliated Hospital Of Fujian Medical University ( Site 2123)
Fuzhou, Fujian, China · Recruiting
Fujian Cancer Hospital ( Site 2122)
Fuzhou, Fujian, China · Recruiting
Sun Yat-sen University Cancer Center ( Site 2134)
Guangzhou, Guangdong, China · Recruiting
Guangxi Medical University Cancer Hospital ( Site 2115)
Nanning, Guangxi, China · Recruiting
Fourth Hospital Of Hebei Medical University ( Site 2107)
Hshijiazhuang, Hebei, China · Recruiting
Tongji Hospital Tongji Medical,Science & Technology ( Site 2140)
Wuhan, Hubei, China · Recruiting
Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 2139)
Wuhan, Hubei, China · Recruiting
Xiangya Hospital Central South University ( Site 2136)
Changsha, Hunan, China · Recruiting
Hunan Cancer Hospital ( Site 2112)
Changsha, Hunan, China · Recruiting
The First Affiliated Hospital of Nanchang University ( Site 2121)
Nanchang, Jiangxi, China · Recruiting
Affiliated Cancer Hospital of Shandong First Medical University ( Site 2111)
Jinan, Shandong, China · Recruiting
Shanghai Pulmonary Hospital ( Site 2125)
Shanghai, Shanghai Municipality, China · Recruiting
Fudan University Shanghai Cancer Center ( Site 2137)
Shanghai, Shanghai Municipality, China · Recruiting
Zhongshan Hospital of Fudan University ( Site 2119)
Shanghai, Shanghai Municipality, China · Recruiting
Showing 40 of 125 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.